Abstract:Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as Xa or thrombin, demonstrated improved safety profiles compared to VKAs, yet bleeding remains a concern. Accordingly, research is focused on developing anticoagulants with improved safety profiles. A safer class of anticoagulants would have broad appeal. The intrinsic pathway of coagulation, involving factor XI (FXI), has attracted attention as a potential target for safer anticoagulants. Preclinical studies and epidemiological data indicate that FXI deficiency or inhibition protects against thrombosis with minimal bleeding. Current research involves evaluating various FXI-directed strategies, and phase 2 studies have shown promising results in orthopedic surgery, atrial fibrillation, end-stage renal disease (ESRD), myocardial infarction, and ischemic stroke. Several agents, such as antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers, have been developed to inhibit FXI at different stages, offering potentially safer alternatives to traditional anticoagulants. However, the optimal balance between preventing thrombosis and the risk of bleeding associated with FXI inhibitors requires validation through extensive phase 3 clinical trials using definite clinical endpoints. Several of such trials are currently underway or planned to define the role of FXI inhibitors in clinical practice and determine the most suitable FXI inhibitor for each specific indication. The current review highlights the rationale behind developing FXI inhibitors, presenting the most advanced agents in development, summarizing completed clinical trials, and discussing ongoing research efforts.

Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation

Factor Ⅺ-a promising anticoagulation target

New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials

A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation

Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors

Discovery and development of Factor Xa inhibitors (2015-2022)

Factor XI: structure, function and therapeutic inhibition

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances

Cyclic Peptide FXII Inhibitor Provides Safe Anticoagulation in a Thrombosis Model and in Artificial Lungs

Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.

Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments

Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors

Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit

Therapeutic Potential of FXI Inhibitors: Hype or Hope?

Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives